Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Anticoagulant-Related Nephropathy.

Brodsky S, Eikelboom J, Hebert LA.

J Am Soc Nephrol. 2018 Dec;29(12):2787-2793. doi: 10.1681/ASN.2018070741. Epub 2018 Nov 12.

PMID:
30420420
2.

The Urine Preservative Acetic Acid Degrades Urine Protein: Implications for Urine Biorepositories and the AASK Cohort Study.

Almaani S, Hebert LA, Rovin BH, Birmingham DJ.

J Am Soc Nephrol. 2017 May;28(5):1394-1398. doi: 10.1681/ASN.2016080886. Epub 2017 Jan 19.

3.

Anticoagulant-Related Nephropathy: Is an AKI Elephant Hiding in Plain View?

Brodsky SV, Hebert LA.

J Am Coll Cardiol. 2016 Nov 29;68(21):2284-2286. doi: 10.1016/j.jacc.2016.09.926. No abstract available.

4.

BP Control and Long-Term Risk of ESRD and Mortality.

Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV, Bakris G, Gutiérrez OM, Hebert LA, Ix JH, Lea J, Lipkowitz MS, Norris K, Ploth D, Pogue VA, Rostand SG, Siew ED, Sika M, Tisher CC, Toto R, Wright JT Jr, Wyatt C, Hsu CY.

J Am Soc Nephrol. 2017 Feb;28(2):671-677. doi: 10.1681/ASN.2016030326. Epub 2016 Aug 11.

5.

Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases.

Lintner KE, Wu YL, Yang Y, Spencer CH, Hauptmann G, Hebert LA, Atkinson JP, Yu CY.

Front Immunol. 2016 Feb 15;7:36. doi: 10.3389/fimmu.2016.00036. eCollection 2016. Review.

6.

Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare.

Birmingham DJ, Bitter JE, Ndukwe EG, Dials S, Gullo TR, Conroy S, Nagaraja HN, Rovin BH, Hebert LA.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):47-53. doi: 10.2215/CJN.03990415. Epub 2015 Dec 23.

7.

The Complement System in Lupus Nephritis.

Birmingham DJ, Hebert LA.

Semin Nephrol. 2015 Sep;35(5):444-54. doi: 10.1016/j.semnephrol.2015.08.006. Review.

PMID:
26573547
8.

In Reply to 'Expanding the Domain of Postinfectious Glomerulonephritis' and 'Postinfectious Versus Infection-Related Glomerulonephritis'.

Hebert LA, Glassock RJ.

Am J Kidney Dis. 2015 Oct;66(4):726. doi: 10.1053/j.ajkd.2015.07.016. No abstract available.

PMID:
26408238
9.

A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).

Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC; Mentor Consortium group.

Nephron. 2015;130(3):159-68. doi: 10.1159/000430849. Epub 2015 Jun 12.

PMID:
26087670
10.

Staphylococcus-related glomerulonephritis and poststreptococcal glomerulonephritis: why defining "post" is important in understanding and treating infection-related glomerulonephritis.

Glassock RJ, Alvarado A, Prosek J, Hebert C, Parikh S, Satoskar A, Nadasdy T, Forman J, Rovin B, Hebert LA.

Am J Kidney Dis. 2015 Jun;65(6):826-32. doi: 10.1053/j.ajkd.2015.01.023. Epub 2015 Apr 15.

PMID:
25890425
11.

Rituximab or azathioprine maintenance in ANCA-associated vasculitis.

Hebert LA, Alvarado A, Rovin B.

N Engl J Med. 2015 Jan 22;372(4):385. doi: 10.1056/NEJMc1414728. No abstract available.

PMID:
25607434
12.

Is fluid overload as measured by bioimpedance spectroscopy harmful in CKD-if so, why?

Hebert LA, Parikh S.

Clin J Am Soc Nephrol. 2015 Jan 7;10(1):1-3. doi: 10.2215/CJN.11311114. Epub 2014 Dec 15. No abstract available.

13.

Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?

Ware KM, Vance JC, Muni N, Hebert LA, Satoskar AA, Nadasdy G, Ivanov I, Nadasdy T, Rovin BH, Brodsky SV.

Am J Hypertens. 2015 Feb;28(2):182-9. doi: 10.1093/ajh/hpu129. Epub 2014 Jul 13.

PMID:
25023204
14.

End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.

Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Alarcón GS, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KL, Niewold TB, Patel NM, Petri M, Ramsey-Goldman R, Reveille JD, Salmon JE, Tsao BP, Gibson KL, Byers JR, Vinnikova AK, Lea JP, Julian BA, Kimberly RP; Lupus Nephritis–End‐Stage Renal Disease Consortium.

Arthritis Rheumatol. 2014 Feb;66(2):390-6. doi: 10.1002/art.38220.

15.

Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease.

Birmingham DJ, Shidham G, Perna A, Fine DM, Bissell M, Rodby R, Remuzzi G, Petri M, Hebert P, Rovin BH, Hebert LA.

Ann Rheum Dis. 2014 Feb;73(2):475-6. doi: 10.1136/annrheumdis-2013-203790. Epub 2013 Oct 3. No abstract available.

16.

Differential diagnosis of glomerular disease: a systematic and inclusive approach.

Hebert LA, Parikh S, Prosek J, Nadasdy T, Rovin BH.

Am J Nephrol. 2013;38(3):253-66. doi: 10.1159/000354390. Epub 2013 Sep 13. Review.

17.

Chronic kidney disease: fluid in chronic kidney disease-how much is too much?

Hebert LA, Parikh S.

Nat Rev Nephrol. 2013 Nov;9(11):630-1. doi: 10.1038/nrneph.2013.196. Epub 2013 Sep 17.

PMID:
24042464
18.

Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.

Roth RM, Benson D, Hebert LA, Bissell MG, Satoskar AA, Nadasdy T, Brodsky SV.

Arch Pathol Lab Med. 2013 Sep;137(9):1304-8. doi: 10.5858/arpa.2012-0159-CR. Review.

PMID:
23991744
19.

N-acetylcysteine ameliorates acute kidney injury but not glomerular hemorrhage in an animal model of warfarin-related nephropathy.

Ware K, Qamri Z, Ozcan A, Satoskar AA, Nadasdy G, Rovin BH, Hebert LA, Nadasdy T, Brodsky SV.

Am J Physiol Renal Physiol. 2013 Jun 15;304(12):F1421-7. doi: 10.1152/ajprenal.00689.2012. Epub 2013 Apr 10.

20.

Unexplained severe acute kidney injury with rapid recovery of kidney function 11 months later after the start of high-dose steroid therapy.

Roncone D, Rovin B, Falk R, Nicely C, Nadasdy T, Parikh S, Hebert LA.

Clin Nephrol. 2014 Aug;82(2):138-43. doi: 10.5414/CN107643.

PMID:
23380388
21.

Novel estrogen target gene ZAS3 is overexpressed in systemic lupus erythematosus.

Young NA, Friedman AK, Kaffenberger B, Rajaram MV, Birmingham DJ, Rovin BH, Hebert LA, Schlesinger LS, Wu LC, Jarjour WN.

Mol Immunol. 2013 May;54(1):23-31. doi: 10.1016/j.molimm.2012.10.026. Epub 2012 Nov 22.

22.

High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus.

Mok CC, Birmingham DJ, Ho LY, Hebert LA, Rovin BH.

Arthritis Care Res (Hoboken). 2013 Mar;65(3):441-7. doi: 10.1002/acr.21841.

23.

Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?

Rovin BH, Parikh SV, Hebert LA, Chan TM, Mok CC, Ginzler EM, Hooi LS, Brunetta P, Maciuca R, Solomons N.

Clin J Am Soc Nephrol. 2013 Jan;8(1):147-53. doi: 10.2215/CJN.03290412. Epub 2012 Aug 9. Review.

24.

5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy.

Ozcan A, Ware K, Calomeni E, Nadasdy T, Forbes R, Satoskar AA, Nadasdy G, Rovin BH, Hebert LA, Brodsky SV.

Am J Nephrol. 2012;35(4):356-64. doi: 10.1159/000337918. Epub 2012 Apr 2.

25.

Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans.

Birmingham DJ, Hebert LA, Song H, Noonan WT, Rovin BH, Nagaraja HN, Yu CY.

Lupus. 2012 Jul;21(8):855-64. doi: 10.1177/0961203312439640. Epub 2012 Mar 20.

26.

Characterization of glomerular diseases using proteomic analysis of laser capture microdissected glomeruli.

Satoskar AA, Shapiro JP, Bott CN, Song H, Nadasdy GM, Brodsky SV, Hebert LA, Birmingham DJ, Nadasdy T, Freitas MA, Rovin BH.

Mod Pathol. 2012 May;25(5):709-21. doi: 10.1038/modpathol.2011.205. Epub 2012 Jan 27.

27.

Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q.

Mok CC, Birmingham DJ, Ho LY, Hebert LA, Song H, Rovin BH.

Lupus. 2012 Jan;21(1):36-42. doi: 10.1177/0961203311422094. Epub 2011 Oct 12.

PMID:
21993384
28.

Benefit of cyclophosphamide therapy in IgA nephritis may have been obscured by warfarin-related nephropathy in the randomized trials in which warfarin and dipyridamole were used in combination with cyclophosphamide.

Brodsky SV, Rovin BH, Hebert LA.

Nephrol Dial Transplant. 2012 Feb;27(2):475-7. doi: 10.1093/ndt/gfr559. Epub 2011 Sep 23. No abstract available.

PMID:
21948859
29.

Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation.

Ware K, Brodsky P, Satoskar AA, Nadasdy T, Nadasdy G, Wu H, Rovin BH, Bhatt U, Von Visger J, Hebert LA, Brodsky SV.

J Am Soc Nephrol. 2011 Oct;22(10):1856-62. doi: 10.1681/ASN.2010101110. Epub 2011 Sep 1.

30.

Infection-related glomerulonephritis: understanding mechanisms.

Nadasdy T, Hebert LA.

Semin Nephrol. 2011 Jul;31(4):369-75. doi: 10.1016/j.semnephrol.2011.06.008. Review.

PMID:
21839370
31.

Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated.

Barnes CE, Wilmer WA, Hernandez RA Jr, Valentine C, Hiremath LS, Nadasdy T, Satoskar AA, Shim RL, Rovin BH, Hebert LA.

Nephron Clin Pract. 2011;119(2):c145-53. doi: 10.1159/000324762. Epub 2011 Jul 8.

32.

Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis.

Mok CC, Birmingham DJ, Leung HW, Hebert LA, Song H, Rovin BH.

Rheumatology (Oxford). 2012 Apr;51(4):644-52. doi: 10.1093/rheumatology/ker212. Epub 2011 Jun 29. Review.

PMID:
21719424
33.

A modest proposal for improving the accuracy of creatinine-based GFR-estimating equations.

Hebert PL, Nori US, Bhatt UY, Hebert LA.

Nephrol Dial Transplant. 2011 Aug;26(8):2426-8. doi: 10.1093/ndt/gfr151. Epub 2011 Mar 29. No abstract available.

34.

An approach to validating criteria for proteinuric flare in systemic lupus erythematosus glomerulonephritis.

Ardoin S, Birmingham DJ, Hebert PL, Yu CY, Rovin BH, Hebert LA.

Arthritis Rheum. 2011 Jul;63(7):2031-7. doi: 10.1002/art.30345.

35.

Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate.

Brodsky SV, Nadasdy T, Rovin BH, Satoskar AA, Nadasdy GM, Wu HM, Bhatt UY, Hebert LA.

Kidney Int. 2011 Jul;80(2):181-9. doi: 10.1038/ki.2011.44. Epub 2011 Mar 9.

36.

Measured GFR has limited clinical utility.

Nori US, Pesavento TE, Hebert LA.

Am J Kidney Dis. 2011 Jan;57(1):180; discussion 180-1. doi: 10.1053/j.ajkd.2010.08.035. No abstract available.

PMID:
21184927
37.

Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.

Hebert LA, Ardoin S, Shim RL.

N Engl J Med. 2010 Nov 18;363(21):2072-3; author reply 2073-4. doi: 10.1056/NEJMc1009101. No abstract available.

PMID:
21083399
38.

Intensive blood-pressure control in hypertensive chronic kidney disease.

Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X; AASK Collaborative Research Group.

N Engl J Med. 2010 Sep 2;363(10):918-29. doi: 10.1056/NEJMoa0910975.

39.

Relationship between body mass index and proteinuria in hypertensive nephrosclerosis: results from the African American Study of Kidney Disease and Hypertension (AASK) cohort.

Toto RD, Greene T, Hebert LA, Hiremath L, Lea JP, Lewis JB, Pogue V, Sika M, Wang X; AASK Collaborative Research Group.

Am J Kidney Dis. 2010 Nov;56(5):896-906. doi: 10.1053/j.ajkd.2010.05.016.

40.

Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care?

Hebert LA, Rovin BH.

Nephron Clin Pract. 2011;117(1):c8-14. doi: 10.1159/000319641. Epub 2010 Aug 3. Review.

41.

The complex nature of serum C3 and C4 as biomarkers of lupus renal flare.

Birmingham DJ, Irshaid F, Nagaraja HN, Zou X, Tsao BP, Wu H, Yu CY, Hebert LA, Rovin BH.

Lupus. 2010 Oct;19(11):1272-80. doi: 10.1177/0961203310371154. Epub 2010 Jul 6.

42.

Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease.

Brodsky SV, Collins M, Park E, Rovin BH, Satoskar AA, Nadasdy G, Wu H, Bhatt U, Nadasdy T, Hebert LA.

Nephron Clin Pract. 2010;115(2):c142-6. doi: 10.1159/000312877. Epub 2010 Apr 22.

43.

Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.

Hebert LA, Rovin BH.

Ann Intern Med. 2010 Jan 5;152(1):64; author reply 65. doi: 10.7326/0003-4819-152-1-201001050-00020. No abstract available.

PMID:
20048278
44.

Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option.

McKinley A, Park E, Spetie D, Hackshaw KV, Nagaraja S, Hebert LA, Rovin BH.

Clin J Am Soc Nephrol. 2009 Nov;4(11):1754-60. doi: 10.2215/CJN.02670409. Epub 2009 Sep 3.

45.

Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients.

Hebert LA, Birmingham DJ, Shidham G, Rovin B, Nagaraja HN, Yu CY.

Nephron Clin Pract. 2009;113(3):c177-82. doi: 10.1159/000232599. Epub 2009 Aug 12.

46.

Uric acid and cardiovascular risk.

Hebert LA, Rovin B.

N Engl J Med. 2009 Jan 29;360(5):540; author reply 540-1. No abstract available.

PMID:
19186313
47.

D-dimer level and the risk for thrombosis in systemic lupus erythematosus.

Wu H, Birmingham DJ, Rovin B, Hackshaw KV, Haddad N, Haden D, Yu CY, Hebert LA.

Clin J Am Soc Nephrol. 2008 Nov;3(6):1628-36. doi: 10.2215/CJN.01480308.

48.

Biomarkers of lupus nephritis determined by serial urine proteomics.

Zhang X, Jin M, Wu H, Nadasdy T, Nadasdy G, Harris N, Green-Church K, Nagaraja H, Birmingham DJ, Yu CY, Hebert LA, Rovin BH.

Kidney Int. 2008 Sep;74(6):799-807. doi: 10.1038/ki.2008.316. Epub 2008 Jul 2.

49.

Relationship between albuminuria and total proteinuria in systemic lupus erythematosus nephritis: diagnostic and therapeutic implications.

Birmingham DJ, Rovin BH, Shidham G, Bissell M, Nagaraja HN, Hebert LA.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1028-33. doi: 10.2215/CJN.04761107. Epub 2008 May 1.

50.

Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus.

Wu YL, Yang Y, Chung EK, Zhou B, Kitzmiller KJ, Savelli SL, Nagaraja HN, Birmingham DJ, Tsao BP, Rovin BH, Hebert LA, Yu CY.

Cytogenet Genome Res. 2008;123(1-4):131-41. doi: 10.1159/000184700. Epub 2009 Mar 11. Review.

Supplemental Content

Loading ...
Support Center